文献速递免疫规划传染病防控与疫情报告

MenB-FHbp疫苗2或3剂基础免疫后hSBA滴度持久性及加强剂免疫原性、安全性至26个月

Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
PubMed 文献 · Vaccine · 2021-06-30

本研究为3期开放标签扩展研究,纳入11-18岁既往接种MenB-FHbp的青少年,评估基础免疫后48个月hSBA滴度持久性及加强剂后26个月免疫应答。结果显示滴度初期下降后稳定至48个月,加强后1个月93.4-100.0%受试者达hSBA滴度≥定量下限,加强免疫安全耐受且诱导免疫记忆持续至26个月。

要点

  • 基础免疫后hSBA滴度12个月内下降,随后稳定至48个月。
  • 加强后1个月93.4-100.0%受试者hSBA滴度≥定量下限。
  • 加强免疫安全耐受,严重全身事件报告率≤3.7%。

核心结论

  • 保护性hSBA滴度初期下降但许多受试者维持4年,加强免疫安全耐受并诱导免疫记忆持续至26个月。
  • 晚期青少年加强接种可能延长MenB疾病保护。

研究设计与样本

  • 3期开放标签扩展研究,延伸自3项2期研究,受试者11-18岁随机接受5种基础免疫程序之一或对照。
  • 基础系列后48个月给予加强剂,持久性阶段698人、加强阶段304人入组。

主要发现

  • 所有组hSBA滴度在基础免疫后12个月内下降,然后稳定至48个月。
  • 加强后1个月,针对各测试菌株93.4-100.0%受试者达hSBA滴度≥定量下限。
  • 加强后12和26个月hSBA滴度百分比高于基础免疫后相同时点。
  • 基础与加强免疫耐受良好,各阶段不良事件报告率≤12.5%。
  • 加强剂局部反应(84.4-93.8%)最常见为注射部位疼痛,全身反应(68.8-76.6%)为疲劳和头痛,严重全身事件≤3.7%。

关键数值与推荐

  • hSBA滴度≥定量下限为保护性指标,加强后1个月达93.4-100.0%。
  • 基础免疫后48个月给予加强剂,评估至加强后26个月。

临床怎么用

  • 对于完成MenB-FHbp基础免疫的青少年,可考虑在晚期青少年加强接种以延长保护。
  • 加强免疫安全耐受,常见反应为注射部位疼痛、疲劳和头痛。

局限性

  • 为开放标签扩展研究,样本量在加强阶段较小(304人)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To demonstrate extended protection against meningococcal serogroup B (MenB) disease after MenB-FHbp (bivalent rLP2086) vaccination, this study evaluated immunopersistence through 26 months following MenB-FHbp boosting after 2 or 3 primary doses in adolescents. STUDY DESIGN: This phase 3, open-label study was an extension of 3 phase 2 studies with participants aged 11-18 years randomized to receive primary MenB-FHbp vaccination following 1 of 5 dosing schedules or control. A booster dose was administered 48 months after the primary series. Immunopersistence through 48 months after the last primary dose (persistence stage) and 26 months postbooster (booster stage) was determined by serum bactericidal assays using human complement (hSBAs) against 4 vaccine-heterologous test strains. Safety evaluations included adverse events (AEs) and local and systemic reactions. RESULTS: Overall, 698 and 304 subjects enrolled in the persistence and booster stages, respectively. hSBA titers declined in all groups during 12 months postprimary vaccination, then remained stable through 48 months. One month postbooster, 93.4-100.0% of subjects achieved hSBA titers ≥ lower limit of quantitation against each test strain; percentages at 12 and 26 months postbooster were higher than at similar time points following primary vaccination. Primary and booster MenB-FHbp vaccinations were well tolerated, with ≤ 12.5% of subjects reporting AEs during each stage. The most common local (reported by 84.4-93.8% of subjects) and systemic (68.8-76.6%) reactions to the booster were injection site pain and fatigue and headache, respectively; ≤ 3.7% of subjects reported severe systemic events. CONCLUSION: Protective hSBA titers initially declined but were retained by many subjects for 4 years irrespective of primary MenB-FHbp vaccination schedule. Boosting at 48 months after primary vaccination was safe, well tolerated, and induced immune responses indicative of immunological memory that persisted through 26 months. Booster vaccination during late adolescence may prolong protection against MenB disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Østergaard L, Vesikari T, Senders SD, et al. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine. 2021. PMID: 34215452. doi:10.1016/j.vaccine.2021.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。